Global biopharmaceutical business AstraZeneca has expanded its presence in Asia by entering two significant relationships with medical companies in China and Japan.
A strategic alliance was announced on December 16, between WuXi AppTec (WuXi), an open-access research and development capability and technology platform company, and, MedImmune, the global biologics research and development arm of AstraZeneca.
{iframe}http://www.asianscientist.com/2015/12/pharma/wuxi-astrazeneca-form-strategic-alliance-expedite-development-astrazenecas-innovative-biologics-portfolio-china/{/iframe}